Madrigal Pharmaceuticals Competitive Intelligence & Landscape

Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to developing and delivering novel therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe liver disease with a high unmet medical need [madrigalpharma.com/about/]. The company’s mission is to halt or reverse liver scarring (fibrosis) and resolve MASH to prevent devastating complications like cirrhosis, liver failure, and liver cancer [madrigalpharma.com/].

Madrigal Pharmaceuticals focuses on innovative research, which has led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH [madrigalpharma.com/]. Their product, a breakthrough treatment, aims to improve care for individuals living with this chronic and progressive condition [madrigalpharma.com/our-medicine/]. The company also provides Madrigal Patient Support, offering assistance with diagnosis, affordability, and patient education [madrigalpharma.com/our-medicine/].

Headquartered at Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428, Madrigal Pharmaceuticals operates with a leadership team committed to innovation and collaboration in MASH treatment [ir.madrigalpharma.com/static-files/6eef839b-62e4-43b6-8111-f3a7f0070c26, madrigalpharma.com/about/our-leaders/]. The company, incorporated in Delaware, is publicly traded on NASDAQ under the ticker MDGL [ir.madrigalpharma.com/static-files/6eef839b-62e4-43b6-8111-f3a7f0070c26, ir.madrigalpharma.com/investor-overview].

The target market for Madrigal Pharmaceuticals includes patients suffering from MASH, a disease where fat in the liver becomes toxic, leading to damage, inflammation, and scarring, potentially resulting in cirrhosis and liver transplantation [madrigalpharma.com/]. The company's commitment extends to corporate giving, making contributions to non-profit organizations [madrigalpharma.com/contact-us/].

Madrigal Pharmaceuticals is a biopharmaceutical company primarily focused on developing novel therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious liver disease with high unmet medical need. Their flagship product, Rezdiffra™ (resmetirom), is an oral THR-β agonist that received the first U.S. Food and Drug Administration (FDA)-approved treatment in MASH, specifically for adults with noncirrhotic MASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise. This approval was granted under an accelerated (conditional) pathway, based on improvements in MASH and fibrosis. The company's pipeline is anchored in advancing therapies for MASH, reflecting their expertise in liver care and commitment to patients.

Madrigal Pharmaceuticals provides transparent pricing information for its prescription drug, Rezdiffra™ (resmetirom), particularly to comply with state regulations. They offer statutory price disclosure notices for prescribers in Colorado, Connecticut, and Vermont. These disclosures typically list the wholesale acquisition cost (“WAC”) prices, often including a 20% markup, as established by third-party publishers or calculated from publicly available data. It's important to note that the actual price paid by consumers may differ from these listed WAC prices.

While Madrigal Pharmaceuticals does not detail tiered pricing plans or free vs. paid features in the traditional software-as-a-service sense, they emphasize patient support to address affordability. This includes assistance for patients at every step of their journey, covering diagnosis, patient education, and affordability. The company acknowledges that product pricing can be subject to various restrictions, including those at the state government level, and limitations on discounts to patients, which influence the final cost to consumers.

As a biopharmaceutical company, their

Madrigal Pharmaceuticals demonstrates a robust and expanding hiring trend, signaling a strategic focus on growth and market leadership in the biopharmaceutical sector. The company, which began as a small research team, has evolved into a fully integrated biopharmaceutical entity with hundreds of employees across the United States and Europe [madrigalpharma.com/about/]. This expansion is underscored by significant appointments, such as Ronald Filippo joining as Chief Information Officer in November 2023 [ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-appoints-ronald-filippo-chief], and Bill Sibold being appointed CEO in anticipation of a first-to-market launch [madrigalpharma.com/about/].

The hiring patterns at Madrigal Pharmaceuticals reflect its commitment to leading the fight against Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company's career page explicitly invites individuals interested in transforming care for people living with MASH to explore life at Madrigal, emphasizing their shared purpose and core values [madrigalpharma.com/careers-culture/]. This focus on talent acquisition aligns with their ambitious research program and the recent U.S. FDA approval of their first treatment for MASH [madrigalpharma.com/].

Recent announcements of inducement awards granted under Nasdaq Listing Rule 5635(c)(4) in April and May 2026 further indicate ongoing recruitment efforts and the strategic onboarding of new employees [ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-grants-inducement-awards-16, ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-grants-inducement-awards-18]. These awards are typically utilized to attract and retain key talent, highlighting Madrigal's active pursuit of skilled professionals to support its expanding operations and market penetration.

While specific layoff information is not available from the provided sources, the overall hiring trends and leadership appointments strongly suggest a period of significant expansion and investment in human capital. The company's emphasis on delivering novel therapeutics for MASH and its transition to a fully integrated biopharma company necessitates a growing workforce across various functions, from research and development to commercial and administrative roles.

In essence, Madrigal Pharmaceuticals is actively recruiting and expanding its team, particularly in areas that will support the development, commercialization, and patient support for their breakthrough MASH treatment. This signals a company in a high-growth phase, strategically investing in its human resources to solidify its position as a leader in the treatment of MASH [madrigalpharma.com/careers-culture/, madrigalpharma.com/about/our-leaders/].

Madrigal Pharmaceuticals has demonstrated significant financial growth, primarily driven by the sales of Rezdiffra (resmetirom), their breakthrough treatment for MASH. In the fourth quarter of 2025, net sales for Rezdiffra reached $321.1 million, contributing to a full-year 2025 total of $958.4 million. This builds on previous quarters, with $287.3 million in Q3 2025, $212.8 million in Q2 2025, and $137.3 million in Q1 2025. The company's financial health is further supported by strong cash reserves, reporting $988.6 million in cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2025 [https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0].

Madrigal Pharmaceuticals has also actively engaged in strategic financial activities and M&A. In July 2025, the company secured up to $500 million in senior secured credit through a facility with funds managed by Blue Owl Capital [https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-second-quarter-2025-financial]. This was preceded by an announced global licensing agreement for an oral GLP-1 development candidate (MGL-2086), which was completed in Q3 2025 [https://ir.madrigalpharma.com/static-files/53eb38ca-4220-47e3-a18a-15d9723198b].

Looking back at previous years, Madrigal Pharmaceuticals reported full-year 2024 Rezdiffra net sales of $180.1 million, with $103.3 million in the fourth quarter of that year [https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year]. The company's market valuation, based on stock held by affiliates as of a business day in 2025, was approximately $5.4 billion [https://ir.madrigalpharma.com/static-files/6eef839b-62e4-43b6-8111-f3a7f0070c26]. The consistent growth in Rezdiffra sales, exceeding $1 billion on an annualized basis in 3Q25, and strategic financial moves underscore Madrigal Pharmaceuticals' robust financial performance and commitment to expanding its therapeutic pipeline for MASH [https://ir.madrigalpharma.com/static-files/53eb38ca-4220-47e3-a18a-15d9723198b].

Madrigal Pharmaceuticals actively participates in a variety of investor conferences and earnings calls, demonstrating their engagement with the financial community and commitment to transparency. Notable past and upcoming participations include the Annual Global Goldman Sachs Health Care Conference, the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company also holds regular earnings calls, such as the Q1 2026 Earnings Call on May 6, 2026, and the Q4 2025 Earnings Call on February 19, 2026.

Further demonstrating their presence at key financial events, Madrigal Pharmaceuticals attended the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and the 8th Annual Evercore Healthcare Conference on December 2, 2025. They also announced participation in three investor conferences in November 2025, including the Jefferies Global Healthcare Conference in London, according to a press release from November 17, 2025 "Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences".

Madrigal Pharmaceuticals has a consistent history of attending prominent healthcare investment conferences. For instance, they participated in the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. These events provide opportunities for the company to present its financial results, pipeline advancements, and strategic outlook to investors and analysts.